Model/tool |
Owner of the tool |
Nanospecific
|
Type of tool
|
Application domain
|
Applicable roots of release and exposure
|
Applicable R&I phase
|
Cooper stage-gate
|
Applicable population
|
Applicable products with EU regulations
|
Applicable material
|
Difficulty
|
Tool output
|
Short description of tool and references |
Stoffenmanager Nano | Cosanta BV | 1. Yes | 1. Control banding | 3. Risk assessment (hazard and exposure) | 1. Inhalation only | 1. Design phase | 4. R&D | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 1. 1-1.9 | 2. Semi-quantitative | https://nano.stoffenmanager.com/Default.aspx?lang=en |
Stoffenmanager Nano | | | | | | 2. Market phase | | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Stoffenmanager Nano | | | | | | | | | 3. Medical devices | 3. Liquid dispersion | | | |
Stoffenmanager Nano | | | | | | | | | 4. Biocides | 4. Solid reinforced composite | | | |
Stoffenmanager Nano | | | | | | | | | 5. Food contact materials | | | | |
Stoffenmanager Nano | | | | | | | | | 6. Food labelling | | | | |
Stoffenmanager Nano | | | | | | | | | 7. Drugs | | | | |
Nanosafer CB | NRCWE | 1. Yes | 1. Control banding | 3. Risk assessment (hazard and exposure) | 1. Inhalation only | 1. Design phase | 1. Idea | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 1. 1-1.9 | 2. Semi-quantitative | http://www.nanosafer.org/ |
Nanosafer CB | | | 5. Numerical estimate | | | | 2. Screening | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Nanosafer CB | | | | | | | 3. Buisness case | | 3. Medical devices | | | | |
Nanosafer CB | | | | | | | 4. R&D | | 4. Biocides | | | | |
Nanosafer CB | | | | | | | 5. validation | | 5. Food contact materials | | | | |
Nanosafer CB | | | | | | | 6. Launch | | 6. Food labelling | | | | |
Nanosafer CB | | | | | | | 7. Monitoring | | 7. Drugs | | | | |
GUIDEnano | LEITAT | 1. Yes | 5. Numerical estimate | 3. Risk assessment (hazard and exposure) | 1. Inhalation only | 1. Design phase | 2. Screening | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 1. 1-1.9 | 3. Quantitative | https://tool.guidenano.eu/Home/About |
GUIDEnano | | | | | | 2. Market phase | 3. Buisness case | 2. Worker | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
GUIDEnano | | | | | | | 4. R&D | 3. Consumer | 3. Medical devices | 3. Liquid dispersion | | | |
GUIDEnano | | | | | | | 5. validation | 4. General population | 4. Biocides | 4. Solid reinforced composite | | | |
GUIDEnano | | | | | | | 6. Launch | | 5. Food contact materials | | | | |
GUIDEnano | | | | | | | 7. Monitoring | | 6. Food labelling | | | | |
GUIDEnano | | | | | | | | | 7. Drugs | | | | |
RiskofDerm | TNO | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 2. Dermal only | 1. Design phase | 1. Idea | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 1. 1-1.9 | 3. Quantitative | https://www.eurofins.com/media/2245/dermal_toolkit_paper_version-en.pdf |
RiskofDerm | | | | | | 2. Market phase | 2. Screening | | 4. Biocides | 2. Powdered non-spherical particulate | | | |
RiskofDerm | | | | | | 3. Regulatory phase | 3. Buisness case | | | | | | |
RiskofDerm | | | | | | | 4. R&D | | | | | | |
RiskofDerm | | | | | | | 5. validation | | | | | | |
RiskofDerm | | | | | | | 6. Launch | | | | | | |
RiskofDerm | | | | | | | 7. Monitoring | | | 3. Liquid dispersion | | | |
LICARA nanoSCAN | TNO/EMPA | 1. Yes | 2. Risk Screening | 3. Risk assessment (hazard and exposure) | 1. Inhalation only | 1. Design phase | 1. Idea | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 1. 1-1.9 | 1. Qualitative | http://publicationslist.org/data/nowack/ref-160/2014_09_29_Licara%20Guidelines_m_links[1].pdf |
LICARA nanoSCAN | | | 3. Life cycle assessment | 4. Risk-benefit analysis | | | 2. Screening | 2. Worker | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
LICARA nanoSCAN | | | | | | | 3. Buisness case | 3. Consumer | | 3. Liquid dispersion | | | |
LICARA nanoSCAN | | | | | | | | 4. General population | 4. Biocides | 4. Solid reinforced composite | | | |
LICARA nanoSCAN | | | | | | | | | | | | | |
LICARA nanoSCAN | | | | | | | | | | | | | |
LICARA nanoSCAN | | | | | | | | | | | | | |
Swiss precautionary matrix | Swiss Federal Office of Public Health | 1. Yes | 2. Risk Screening | 1. Release/exposure assessment | 4. All routes | 1. Design phase | 3. Buisness case | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 1. 1-1.9 | 1. Qualitative | https://www.bag.admin.ch/bag/en/home/gesund-leben/umwelt-und-gesundheit/chemikalien/nanotechnologie/sicherer-umgang-mit-nanomaterialien/vorsorgeraster-nanomaterialien-downloadversion.html |
Swiss precautionary matrix | | | 3. Life cycle assessment | 2. Hazard assessment | | | 4. R&D | 2. Worker | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Swiss precautionary matrix | | | | | | | 5. validation | 3. Consumer | 3. Medical devices | 3. Liquid dispersion | | | |
Swiss precautionary matrix | | | | | | | 6. Launch | | 4. Biocides | 4. Solid reinforced composite | | | |
Swiss precautionary matrix | | | | | | | 7. Monitoring | | 5. Food contact materials | | | | |
Swiss precautionary matrix | | | | | | | | | 6. Food labelling | | | | |
Swiss precautionary matrix | | | | | | | | | 7. Drugs | | | | |
Control Banding Nanotool | Lawrence Livermore National Laboratory | 1. Yes | 1. Control banding | 3. Risk assessment (hazard and exposure) | 4. All routes | 1. Design phase | | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 1. Qualitative | https://controlbanding.llnl.gov/ |
Control Banding Nanotool | | | | | | | | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Control Banding Nanotool | | | | | | | | | 3. Medical devices | 3. Liquid dispersion | | | |
Control Banding Nanotool | | | | | | | | | 4. Biocides | 4. Solid reinforced composite | | | |
Control Banding Nanotool | | | | | | | | | 5. Food contact materials | | | | |
Control Banding Nanotool | | | | | | | | | 6. Food labelling | | | | |
Control Banding Nanotool | | | | | | | | | 7. Drugs | | | | |
DeRmal Exposure Assessment Method (DREAM) | TNO | 2. No | 2. Risk Screening | 1. Release/exposure assessment | 2. Dermal only | 1. Design phase | | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 2. Semi-quantitative | https://academic.oup.com/annweh/article/47/1/71/131394 |
DeRmal Exposure Assessment Method (DREAM) | | | | | | 2. Market phase | | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
DeRmal Exposure Assessment Method (DREAM) | | | | | | | | | 3. Medical devices | 3. Liquid dispersion | | | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1741090/ |
DeRmal Exposure Assessment Method (DREAM) | | | | | | | | | 4. Biocides | | | | |
DeRmal Exposure Assessment Method (DREAM) | | | | | | | | | 5. Food contact materials | | | | |
DeRmal Exposure Assessment Method (DREAM) | | | | | | | | | 6. Food labelling | | | | |
DeRmal Exposure Assessment Method (DREAM) | | | | | | | | | 7. Drugs | | | | |
DeRmal Exposure Assessment Method (DREAM) | | | | | | | | | | | | | |
ECETOC TRA | ECETOC | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 2. Semi-quantitative | http://www.ecetoc.org/tools/targeted-risk-assessment-tra/ |
ECETOC TRA | | | | | 2. Dermal only | 2. Market phase | | 2. Worker | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
ECETOC TRA | | | | | | 3. Regulatory phase | | 3. Consumer | 3. Medical devices | 3. Liquid dispersion | | | |
ECETOC TRA | | | | | | | | | 4. Biocides | 4. Solid reinforced composite | | | |
ECETOC TRA | | | | | | | | | 5. Food contact materials | | | | |
ECETOC TRA | | | | | | | | | 6. Food labelling | | | | |
ECETOC TRA | | | | | | | | | 7. Drugs | | | | |
Consexpo Nano Tool | RIVM | 1. Yes | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | 2. Screening | 3. Consumer | 1. Chemical substances | 3. Liquid dispersion | 1. 1-1.9 | 3. Quantitative | https://www.rivm.nl/en/consexpo/related-tools/nano-tool/about |
Consexpo Nano Tool | | | | | | | 3. Buisness case | | | | | | |
Consexpo Nano Tool | | | | | | | 4. R&D | | | | | | |
Consexpo Nano Tool | | | | | | | 5. validation | | | | | | |
Consexpo Nano Tool | | | | | | | 6. Launch | | | | | | |
Consexpo Nano Tool | | | | | | | 7. Monitoring | | 4. Biocides | | | | |
Advanced REACH Tool (ART) | HSL | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | 2. Screening | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | https://www.advancedreachtool.com/ |
Advanced REACH Tool (ART) | | | | | | 2. Market phase | 3. Buisness case | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Advanced REACH Tool (ART) | | | | | | 3. Regulatory phase | 4. R&D | | 3. Medical devices | 3. Liquid dispersion | | | |
Advanced REACH Tool (ART) | | | | | | | 5. validation | | 4. Biocides | 4. Solid reinforced composite | | | |
Advanced REACH Tool (ART) | | | | | | | 6. Launch | | 5. Food contact materials | | | | |
Advanced REACH Tool (ART) | | | | | | | 7. Monitoring | | 6. Food labelling | | | | |
Advanced REACH Tool (ART) | | | | | | | | | 7. Drugs | | | | |
Advanced REACH Tool (ART) | | | | | | | | | | | | | |
SprayExpo model | BAUA | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | 2. Screening | 2. Worker | 1. Chemical substances | 3. Liquid dispersion | 6. N/A | 3. Quantitative | https://www.baua.de/EN/Topics/Work-design/Hazardous-substances/Assessment-unit-biocides/Sprayexpo.html |
SprayExpo model | | | | | 2. Dermal only | 2. Market phase | 3. Buisness case | | 4. Biocides | | | | https://www.baua.de/DE/Angebote/Publikationen/Berichte/F2137.pdf?__blob=publicationFile&v=2 |
SprayExpo model | | | | | | | 4. R&D | | | | | | |
SprayExpo model | | | | | | | 5. validation | | | | | | |
SprayExpo model | | | | | | | 6. Launch | | | | | | |
SprayExpo model | | | | | | 3. Regulatory phase | 7. Monitoring | | | | | | |
British Aerosol Manufacturers Association indoor air model | British Aerosol Manufacturers Association (BAMA) | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | | 2. Worker | 1. Chemical substances | 3. Liquid dispersion | 6. N/A | 3. Quantitative | https://www.bama.co.uk/product.php?product_id=11 |
British Aerosol Manufacturers Association indoor air model | | | | | 2. Dermal only | 2. Market phase | | 3. Consumer | 4. Biocides | | | | |
British Aerosol Manufacturers Association indoor air model | | | | | | 3. Regulatory phase | | | | | | | |
NANOSOLUTIONS | FIOH | 1. Yes | 2. Risk Screening | 2. Hazard assessment | N/A | 1. Design phase | | 2. Worker | 1. Chemical substances | N/A | 6. N/A | 2. Semi-quantitative | http://nanosolutionsfp7.com/publications/publications/ |
NANOSOLUTIONS | | | | | | | | 3. Consumer | 2. Cosmetic products | | | | |
NANOSOLUTIONS | | | | | | | | 4. General population | 3. Medical devices | | | | |
NANOSOLUTIONS | | | | | | | | | 4. Biocides | | | | |
NANOSOLUTIONS | | | | | | | | | 5. Food contact materials | | | | |
NANOSOLUTIONS | | | | | | | | | 6. Food labelling | | | | |
NANOSOLUTIONS | | | | | | | | | 7. Drugs | | | | |
ESIG-EGRET | European Solvents Industry Group (ESIG) | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | | 3. Consumer | 1. Chemical substances | 3. Liquid dispersion | 6. N/A | 2. Semi-quantitative | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941027/pdf/jes2012128a.pdf |
ESIG-EGRET | | | 6. Database | | 2. Dermal only | 2. Market phase | | | 2. Cosmetic products | | | | |
ESIG-EGRET | | | | | | 3. Regulatory phase | | | 3. Medical devices | | | | https://www.esig.org/reach-ges/consumers/ |
ESIG-EGRET | | | | | | | | | 4. Biocides | | | | |
ESIG-EGRET | | | | | | | | | 5. Food contact materials | | | | |
ESIG-EGRET | | | | | | | | | 6. Food labelling | | | | |
ESIG-EGRET | | | | | | | | | 7. Drugs | | | | |
ESIG-EGRET | | | | | | | | | | | | | |
SimpleBox4Nano screening fate assessment model | RIVM | 1. Yes | 5. Numerical estimate | 1. Release/exposure assessment | 5. Environmental | 3. Regulatory phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 2. 2-2.9 | 3. Quantitative | SimpleBox4nano is a regulatory-relevant multimedia fate model that is specifically fit for use with nanomaterials. The tool predicts background concentrations of nanomaterials in air, water, sediment and soil using nested regional, continental and global scale compartments. |
SimpleBox4Nano screening fate assessment model | | | | 8. Environmental fate | | | | | 4. Biocides | | | | |
SimpleBox4Nano screening fate assessment model | | | | | | | | | | | | | |
SimpleBox4Nano screening fate assessment model | | | | | | | | | | | | | |
SimpleBox4Nano screening fate assessment model | | | | | | | | | 5. Food contact materials | | | | |
SimpleBox4Nano screening fate assessment model | | | | | | | | | 6. Food labelling | | | | |
SimpleBox4Nano screening fate assessment model | | | | | | | | | 7. Drugs | | | | |
SimpleBox4Nano screening fate assessment model | | | | | | | | | | | | | |
SUNDS | Universita Ca' Foscari Venezia | 1. Yes | 2. Risk Screening | 3. Risk assessment (hazard and exposure) | 4. All routes | 1. Design phase | 1. Idea | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 2. 2-2.9 | 1. Qualitative | https://cordis.europa.eu/docs/results/604/604305/final1-sun-final-report-20170525.pdf |
SUNDS | | | 3. Life cycle assessment | 4. Risk-benefit analysis | | 2. Market phase | 2. Screening | 2. Worker | 2. Cosmetic products | 2. Powdered non-spherical particulate | | 3. Quantitative | |
SUNDS | | | 5. Numerical estimate | 5. Social impact assessment | | 3. Regulatory phase | 3. Buisness case | 3. Consumer | 3. Medical devices | 3. Liquid dispersion | | | |
SUNDS | | | | 6. Economic impact assessment | | | 4. R&D | 4. General population | 4. Biocides | 4. Solid reinforced composite | | | |
SUNDS | | | | | | | 5. validation | | 5. Food contact materials | | | | |
SUNDS | | | | | | | 6. Launch | | 6. Food labelling | | | | |
SUNDS | | | | | | | 7. Monitoring | | 7. Drugs | | | | |
SUNDS | | | | | | | | | | | | | |
Multiple-Path Particle Dosimetry Model (MPPD v 3.04) | ARA (Applied research associates) | 3. Partly | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | Computational particle dosimetry model for airborne particles that can be used for estimating human and test animal airway particle dosimetry. The model is applicable to risk assessment, research, and education. The MPPD model calculates the deposition and clearance of monodisperse and polydisperse aerosols in the respiratory tracts of rats and human adults and children (deposition only) for particles ranging in size from ultrafine (0.01 µm) to coarse (20 µm). The models are based on single-path and multiple-path methods for tracking air flow and calculating aerosol deposition in the lung. The single-path method calculates deposition in a typical path per airway generation, while the multiple-path method calculates particle deposition in all airways of the lung and provides lobar-specific and airway-specific information. Within each airway, deposition is calculated using theoretically derived efficiencies for deposition by diffusion, sedimentation, and impaction within the airway or airway bifurcation. Filtration of aerosols by the nose and mouth is determined using empirical efficiency functions. The MPPD model includes calculations of particle clearance in the lung following deposition. |
Multiple-Path Particle Dosimetry Model (MPPD v 3.04) | | | | | | 2. Market phase | | 3. Consumer | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Multiple-Path Particle Dosimetry Model (MPPD v 3.04) | | | | | | 3. Regulatory phase | | 4. General population | 3. Medical devices | 3. Liquid dispersion | | | http://www.ara.com/products/mppd.htm |
Multiple-Path Particle Dosimetry Model (MPPD v 3.04) | | | | | | | | | 4. Biocides | 4. Solid reinforced composite | | | |
Multiple-Path Particle Dosimetry Model (MPPD v 3.04) | | | | | | | | | 5. Food contact materials | | | | |
Multiple-Path Particle Dosimetry Model (MPPD v 3.04) | | | | | | | | | 6. Food labelling | | | | |
Multiple-Path Particle Dosimetry Model (MPPD v 3.04) | | | | | | | | | 7. Drugs |
Dynamic probabilistic material flow model (DP-MFA) | EMPA | 1. Yes | 5. Numerical estimate | 1. Release/exposure assessment | 5. Environmental | 3. Regulatory phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 4. 4-4.9 | 3. Quantitative | A DPMFA modeling framework combining dynamic material flow modeling with probabilistic modeling. Material transfers that lead to particular environmental stocks are represented as systems of mass-balanced flows. The time-dynamic behavior of the system is calculated by adding up the flows over several consecutive periods, considering changes in the inflow to the system and intermediate delays in local stocks. Incomplete parameter knowledge is represented and propagated using Bayesian modeling. The method is implemented as a simulation framework in Python to support experts from different domains in the development of their application models. |
Dynamic probabilistic material flow model (DP-MFA) | | | | | | | | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Dynamic probabilistic material flow model (DP-MFA) | | | | | | | | | 3. Medical devices | 3. Liquid dispersion | | | https://pypi.python.org/pypi/dpmfa-simulator |
Dynamic probabilistic material flow model (DP-MFA) | | | | | | | | | 4. Biocides | 4. Solid reinforced composite | | | |
Dynamic probabilistic material flow model (DP-MFA) | | | | | | | | | 5. Food contact materials | | | | |
Dynamic probabilistic material flow model (DP-MFA) | | | | | | | | | 6. Food labelling | | | | |
Dynamic probabilistic material flow model (DP-MFA) | | | | | | | | | 7. Drugs | | | | |
NanoDUFLOW | Wageingen University & Research (WUR) | 1. Yes | 5. Numerical estimate | 8. Environmental fate | 5. Environmental | 3. Regulatory phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 5. = 5 | 3. Quantitative | NanoDUFLOW is a spatially resolved hydrological ENP fate model, that was validated using measurements of inert particulates. |
NanoDUFLOW | | | | | | | | | 4. Biocides | | | | |
NanoDUFLOW | | | | | | | | | | | | | |
NanoDUFLOW | | | | | | | | | | | | | |
DF4nanoGrouping | ECETOC | 1. Yes | 4. Framework | 2. Hazard assessment | 1. Inhalation only | 3. Regulatory phase | | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 1. Qualitative | A decision analytical tool to facilitate the grouping of NMs for the purpose of read-across for RA was proposed by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) ”Nano Task Force”. The tool consists of 3 tiers to assign NMs to 4 main groups: i) soluble NMs, ii) biopersistent high aspect ratio NMs, iii) passive NMs, and iv) active NMs. The tool performs sub-grouping within the main groups to determine and refine nanospecific information needs. The DF4nanoGrouping approach covers all relevant aspects of NM life cycles and biological pathways such as intrinsic material and system-dependent properties, biopersistence, uptake and biodistribution, cellular and apical toxic effects. Use, release and route of exposure are applied as 'qualifiers' in order to determine if the NM can be released from a product matrix; if not, the tool could suggest waiving of irrelevant testing. One distinguishing nanospecific feature of DF4nanoGrouping is that it groups NMs by their specific modes of action that result in apical toxic effects. |
DF4nanoGrouping | | | | | | | | 3. Consumer | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
DF4nanoGrouping | | | | | | | | 4. General population | | 3. Liquid dispersion | | | http://www.ecetoc.org/topics/nanotechnology/ |
DF4nanoGrouping | | | | | | | | | | 4. Solid reinforced composite | | | |
ISO/TS 12901-2:2014 Nanotechnologies | ISO | 1. Yes | 7. Guidance document | 3. Risk assessment (hazard and exposure) | 1. Inhalation only | 1. Design phase | 1. Idea | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 3. 3-3.9 | 2. Semi-quantitative | ISO/TS 12901-2:2014 Nanotechnologies - Occupational risk management applied to engineered nanomaterials - Part 2: Use of the control banding approach |
Occupational risk management applied to engineered nanomaterials | | | | | | 3. Regulatory phase | 2. Screening | | | 2. Powdered non-spherical particulate | | | |
Part 2: Use of the control banding approach | | | | | | | 3. Buisness case | | | 3. Liquid dispersion | | | https://www.iso.org/standard/53375.html |
| | | | | | | 4. R&D | | | 4. Solid reinforced composite | | | |
Bayesian Networks | NanoNextNL | 1. Yes | 2. Risk Screening | 2. Hazard assessment | 4. All routes | 1. Design phase | | 2. Worker | 1. Chemical substances | | 6. N/A | 3. Quantitative | A Bayesian Network (BN) for the prediction of the hazard potential and biological effects with the focus on metal- and metal-oxide NMs to support human health risk assessment. The developed BN captures the (inter)relationships between the exposure route, the NMs' physicochemical properties and the ultimate biological effects in a holistic manner and was based on international expert consultation and the scientific literature (e.g., in vitro/in vivo data). The BN was validated with independent data extracted from published studies and the accuracy of the prediction of the nanomaterials hazard potential was 72% and for the biological effect 71%, respectively. It is demonstrated that the BN may be used by different stakeholders at several stages in the risk assessment to predict certain properties of NMs of which little information is available or to prioritize NMs for further screening. |
Bayesian Networks | | | 5. Numerical estimate | | | 2. Market phase | | 3. Consumer | | | | | Marvin HJP, Bouzembrak Y, Janssen EM, van der Zande M, Murphy F, Sheehan B, Mullins M, Bouwmeester H, 2017. Application of Bayesian networks for hazard |
Bayesian Networks | | | | | | 3. Regulatory phase | | 4. General population |
Nano Species Sensitivity Weighted Distribution (n-SSWD) | Department of Environmental Sciences, Informatics, and Statistics, University Ca’ Foscari, Venice | 1. Yes | 5. Numerical estimate | 2. Hazard assessment | 5. Environmental | 1. Design phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | An approach to the ecological risk assessment of engineered NMs is proposed that can operate in the context of high uncertainty. This approach further develops species sensitivity weighted distribution (SSWD) by including three weighting criteria (species relevance, trophic level abundance, and nanotoxicity data quality) to address nanospecific needs. |
Nano Species Sensitivity Weighted Distribution (n-SSWD) | | | | | | 2. Market phase | | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | Semenzin E, Lanzellotto E, Hristozov D, Critto A, Zabeo A, Giubilato E, Marcomini A, 2015. Species sensitivity weighted distribution for ecological risk assessment of engineered nanomaterials: The n-TiO2 case study. Environmental Toxicology and Chemistry 34 (11): 2644–2659, DOI: 10.1002/etc.3103 |
Nano Species Sensitivity Weighted Distribution (n-SSWD) | | | | | | 3. Regulatory phase | | | 3. Medical devices | 3. Liquid dispersion | | | |
Nano Species Sensitivity Weighted Distribution (n-SSWD) | | | | | | | | | 4. Biocides | 4. Solid reinforced composite | | | |
Nano Species Sensitivity Weighted Distribution (n-SSWD) | | | | | | | | | 5. Food contact materials | | | | |
Nano Species Sensitivity Weighted Distribution (n-SSWD) | | | | | | | | | 6. Food labelling | | | | |
Nano Species Sensitivity Weighted Distribution (n-SSWD) | | | | | | | | | 7. Drugs | | | | |
NanoProteinCorona (Enalos platform) | NanoMILE / NovaMechanics Ltd | 1. Yes | 8. Guidance tool | 2. Hazard assessment | 4. All routes | 3. Regulatory phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | A predictive model for the assessment of the biological response of surface-modified gold NPs in the form of cellular association, including both internalized and surface-attached NPs, based on their physicochemical properties and protein corona fingerprints. A dataset of 105 unique NPs was used for developing the model. Cellular association is relevant to inflammatory responses, biodistribution, and toxicity in vivo. The validated predictive model is can be used as part of a regulatory or NP safe-by-design decision support system. This online tool allows the virtual screening of NPs to identify those that warrant further toxicity testing on the basis of predicted NP cellular association. https://www.tandfonline.com/doi/full/10.1080/17435390.2018.1504998 |
NanoProteinCorona (Enalos platform) | | | 5. numerical estimate | | | | | 2. Worker | | | | | Afantitis A, Melagraki G, Tsoumanis A, Valsami-Jones E, Lynch I, 2018. A nanoinformatics decision support tool for the virtual screening of gold nanoparticle cellular association using protein corona fingerprints. Nanotoxicology 12 (10): 1148‒1165, DOI: 10.1080/17435390.2018.1504998 |
NanoProteinCorona (Enalos platform) | | | | | | | | 3. Consumer | | | | | |
NanoProteinCorona (Enalos platform) | | | | | | | | 4. General population | | | | | http://enalos.insilicotox.com/NanoProteinCorona/ |
Risk Assessment Tool for the Virtual Screening of NPs (Enalos platform) | NanoMILE / NovaMechanics Ltd | 1. Yes | 5. Numerical estimate | 2. Hazard assessment | 4. All routes | 3. Regulatory phase | | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | A predictive classification model for the toxicological assessment of iron oxide nanoparticles with different core, coating and surface modification based on a number of different properties including size, relaxivities, zeta potential and type of coating. The model successfully fulfilled the criteria recommended by the OECD for model validation, i.e. was validated both internally and externally in terms of goodness-of-fit, robustness and predictivity (see Publication). |
Risk Assessment Tool for the Virtual Screening of NPs (Enalos platform) | | | | 3. Risk assessment and/or management (hazard and exposure) | | | | 3. Consumer | | 2. Powdered non-spherical particulate | | | Lynch I, Afantitis A, Leonis G, Melagraki G, Valsami-Jones E, 2017. Strategy for Identification of Nanomaterials’ Critical Properties Linked to Biological Impacts: Interlinking of Experimental and Computational Approaches. In: Roy K. (eds) Advances in QSAR Modeling. Challenges and Advances in Computational Chemistry and Physics, vol 24. Springer, Cham, pp. 385‒424 Melagraki G, Afantitis A, 2015. A Risk Assessment Tool for the Virtual Screening of Metal Oxide Nanoparticles through Enalos InSilicoNano Platform. Current Topics in Medicinal Chemistry 15(18): 1827‒1836, DOI: 10.2174/1568026615666150506144536 |
Risk Assessment Tool for the Virtual Screening of NPs (Enalos platform) | | | | | | | | 4. General population | | | | | http://www.insilicotox.com/index.php/products/predictive-models-web-services/risk-assessment-tool-for-the-virtual-screening-of-nps/ |
nano-lazar | eNanoMapper | 1. Yes | 4. Framework | 2. Hazard assessment | 4. All routes | 1. Design phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | | nano-lazar is a modular framework for read-across predictions of chemical toxicities. Within the eNanoMapper project, lazar was extended with capabilities to handle nanomaterial data, interfaces to other eNanoMapper services (databases from data.enanomapper.net and ontologies) and a stable and user-friendly graphical interface for nanoparticle read-across predictions. |
nano-lazar | | | | | | 2. Market phase | | 2. Worker | | 2. Powdered non-spherical particulate | | | Helma C, Rautenberg M, Gebele D, 2017. Nano-Lazar: Read across Predictions for Nanoparticle Toxicities with Calculated and Measured Properties. Front. Pharmacol. 8: 377, DOI: 10.3389/fphar.2017.00377 |
nano-lazar | | | | | | 3. Regulatory phase | | 3. Consumer | | 3. Liquid dispersion | | | https://www.enanomapper.net/modelling |
nano-lazar | | | | | | | | 4. General population | | | | | https://nano-lazar.in-silico.ch/ |
In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) | Pacific Northwest National Laboratory and for Nano applications: Harvard University (prof. Philip Demokritou) | 3. Partly | 5. Numerical estimate | 2. Hazard assessment | 4. All routes | 1. Design phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | A computational model to assess the biological effective dose of particles in in vitro systems. The model makes it possible to calculate the per area mass, surface area, and number of particles, as well as the fraction of total suspended material deposited as a function of time. This provides a ground-breaking improvement in dosimetry accuracy and enabled meaningful hazard rankings among NMs. The ISDD software (see Link) is available as code (requiring Matlab) and as a Windows executable file. Adaptations for nanoparticles have been also published (see Publications). |
In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) | | | | | | 2. Market phase | | 2. Worker | 2. Cosmetic products | | | | Hinderliter PM, Minard KR, Orr G, Chrisler WB, Thrall BD, Pounds JG, Teeguarden JG, 2010. ISDD: A computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies. Part Fibre Toxicol 7(1): 36, DOI: 10.1186/1743-8977-7-36 |
|
In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) | | | | | | 3. Regulatory phase | | 3. Consumer | 3. Medical devices | | | | Cohen JM, Teeguarden JG, Demokritou P, 2014. An integrated approach for the in vitro dosimetry of engineered nanomaterials. Part Fibre Toxicol 11: 20, DOI: 10.1186/1743-8977-11-20 |
|
|
In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) | | | | | | | | | 4. Biocides | | | | DeLoid GM, Cohen JM, Pyrgiotakis G, Pirela SV, Pal A, Liu J, Srebric J, Demokritou P, 2015. Advanced computational modeling for in vitro nanomaterial dosimetry. Part Fibre Toxicol 12: 32, DOI: 10.1186/s12989-015-0109-1 |
In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) | | | | | | | | | 5. Food contact materials | | | | Cohen JM, DeLoid GM, Demokritou P, 2015. A critical review of in vitro dosimetry for engineered nanomaterials. Nanomedicine 10(19): 3015‒3032, DOI: 10.2217/nnm.15.129 |
In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) | | | | | | | | | 6. Food labelling | | | | |
In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) | | | | | | | | | 7. Drugs | | | | http://nanodose.pnnl.gov/ |
Nano-QRA | | 1. Yes | 6. Database/management | 2. Hazard assessment | 4. All routes | 1. Design phase | | N/A | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | A quantitative read-across approach for NMs that addresses and overcomes a basic limitation of existing methods with a simple and effective algorithm for filling data gaps in quantitative manner, providing predictions of the missing data. It is based on one-point-slope, two-point formula, or the equation of a plane passing through three points. |
Nano-QRA | | | 7. Guidance document | 7. Material characterization | | | | | | 2. Powdered non-spherical particulate | | | |
Nano-QRA | | | | | | | | | | 3. Liquid dispersion | | | Gajewicz A, Jagiello K, Cronin MTD, Leszczynskic J, Puzyn T, 2017. Addressing a bottle neck for regulation of nanomaterials: quantitative read-across (Nano-QRA) algorithm for cases when only limited data is available. Environ Sci: Nano 4, 346‒358, DOI: 10.1039/C6EN00399K |
Consexpo | RIVM | 2. No | 2. Risk Screening | 1. Release/exposure assessment | 4. All routes | 1. Design phase | 2. Screening | 3. Consumer | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | https://www.rivm.nl/en/consexpo |
Consexpo | | | 5. Numerical estimate | | | 2. Market phase | 3. Buisness case | | 2. Cosmetic products | 2. Powdered non-spherical particulate | | | |
Consexpo | | | | | | 3. Regulatory phase | 4. R&D | | 4. Biocides | | | | |
Consexpo | | | | | | | 5. validation | | | | | | |
Consexpo | | | | | | | 6. Launch | | | | | | |
Consexpo | | | | | | | 7. Monitoring | | | | | | |
Consexpo | | | | | | | | | 5. Food contact materials | | | | |
MEASE | EBRC | 2. No | 5. Numerical estimate | 1. Release/exposure assesment | 1. Inhalation only | 3. Regulatory phase | | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | https://www.ebrc.de/industrial-chemicals-reach/projects-and-references/mease.php |
MEASE | | | | | | | | | | 2. Powdered non-spherical particulate | | | |
MEASE | | | | | | | | | | 3. Liquid suspension | | | |
MEASE | | | | | | | | | | | | | |
ENAE CPSC | NIST | 1. Yes | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 2. Market phase | 2. Screening | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 2. 2-2.9 | 3. Quantitative | https://pages.nist.gov/CONTAM-apps/webapps/NanoParticleTool/index.htm |
ENAE CPSC | | | | | 2. Dermal only | | 3. Buisness case | | | | | | |
ENAE CPSC | | | | | | | 4. R&D | | | | | | |
ENAE CPSC | | | | | | | 5. validation | | | | | | |
ENAE CPSC | | | | | | | 6. Launch | | | | | | |
ENAE CPSC | | | | | | | 7. Monitoring | 3. Consumer | | 2. Powder non-spherical particulate | | | |
EMKG Expo tool | BAuA | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 2. Semi-quantitative | https://www.baua.de/EN/Service/Publications/Guidance/EMKG-Expo-Tool-2.html |
EMKG Expo tool | | | | | | 2. Market phase | | | | 2. Powdered non-spherical particulate | | | |
EMKG Expo tool | | | | | | 3. Regulatory phase | | | | 3. Liquid suspension | | | |
CEM | EPA | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 2. Market phase | | 3. Consumer | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | https://www.epa.gov/tsca-screening-tools/cem-consumer-exposure-model-download-and-install-instructions |
CEM | | | | | 2. Dermal only | | | | | 2. Powdered non-spherical particulate | | | |
CEM | | | | | 3. Ingestion only | | | | | 3. Liquid suspension | | | |
ChemSTEER | EPA | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | https://www.epa.gov/tsca-screening-tools/chemsteer-chemical-screening-tool-exposures-and-environmental-releases |
ChemSTEER | | | | | 2. Dermal only | 2. Market phase | | 2. Worker | | 2. Powdered non-spherical particulate | | | |
ChemSTEER | | | | | | 3. Regulatory phase | | | | 3. Liquid suspension | | | |
E-FAST | EPA | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 1. Design phase | | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | https://www.epa.gov/tsca-screening-tools/e-fast-exposure-and-fate-assessment-screening-tool-version-2014 |
E-FAST | | | | 8. Environmental fate | 2. Dermal only | 2. Market phase | | 2. Worker | | 2. Powdered non-spherical particulate | | | |
E-FAST | | | | | 3. Ingestion only | 3. Regulatory phase | | 3. Consumer | | 3. Liquid suspension | | | |
E-FAST | | | | | | | | 4. General population | | | | | |
WPEM | EPA | 2. No | 5. Numerical estimate | 1. Release/exposure assessment | 1. Inhalation only | 2. Market phase | | 2. Worker | 1. Chemical substances | 3. Liquid suspension | 6. N/A | 3. Quantitative | https://www.epa.gov/tsca-screening-tools/wpem-wall-paint-exposure-model-questions-and-answers |
WPEM | | | | | | | | 3. Consumer | | | | | |
BIORIMA (Risk assessemnt and risk control module - Occupational exposure section) | ITENE | 1. Yes | 5. Numerical estimate | 3. Risk assessment (hazard and exposure) | 4. All routes | 1. Design phase | 1. Idea | 1. Environment | 1. Chemical substances | 1. Powdered spherical particulate | | 3. Quantitative | https://sunds.gd/biorima/biorimaSelection |
BIORIMA (Risk assessemnt and risk control module - Occupational exposure section) | | | | | | 2. Market phase | 2. Screening | 2. Worker | 3.Medical devices | 3. Liquid disperion | 1. 1-1.9 | | |
BIORIMA (Risk assessemnt and risk control module - Occupational exposure section) | | | | | | 3. Regulatory phase | 3. Buisness case | | | | | | |
BIORIMA (Risk assessemnt and risk control module - Occupational exposure section) | | | | | | | 4. R&D | | | | | | |
Stoffenmanager | Cosanta BV | 2. No | 5. Numerical estimate | 3. Risk assessment (hazard and exposure) | 1. Inhalation only | 1. Design phase | 1. Idea | 2. Worker | 1. Chemical substances | 1. Powdered spherical particulate | 6. N/A | 3. Quantitative | |
Stoffenmanager | | | | | | 2. Market phase | 2. Screening | | | 3. Liquid dispersion | | | |
Stoffenmanager | | | | | | 3. Regulatory phase | 3. Buisness case | | | | | | |
Stoffenmanager | | | | | | | 4. R&D | | | | | | |
Stoffenmanager | | | | | | | 5. validation | | | | | | |
Stoffenmanager | | | | | | | 6. Launch |